NCT04970212: Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

NCT04970212
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 21 Years and older (Adult, Older Adult)
Location of Metastases: Liver
Additional Notes: Patient must be scheduled for liver tissue ablation
Exclusions: 
https://ClinicalTrials.gov/show/NCT04970212

Comments are closed.

Up ↑